Compare PDLB & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PDLB | LXEO |
|---|---|---|
| Founded | 1960 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.1M | 396.5M |
| IPO Year | 2021 | 2023 |
| Metric | PDLB | LXEO |
|---|---|---|
| Price | $20.29 | $4.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 63.0K | ★ 679.5K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 39.81 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.91 | $3.99 |
| 52 Week High | $21.10 | $10.99 |
| Indicator | PDLB | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 39.07 |
| Support Level | $19.66 | $4.01 |
| Resistance Level | $20.81 | $5.38 |
| Average True Range (ATR) | 0.40 | 0.24 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 56.12 | 5.59 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.